antibodies

When a person with rheumatoid arthritis receives healthy antibodies intravenously, it can reduce inflammation. Researchers have, for the first time, discovered the molecular pathways that underlie this effect, paving the way for new treatments.

A Phase 3 clinical trial of the drug donanemab has shown it can significantly slow cognitive and functional decline in people with early-stage Alzheimer’s disease, compared with existing treatments.

Researchers have discovered new information about how the body’s antibody-mediated immune system works, calling into question long-held scientific understanding and opening the door for potential advancements in immunological treatment.

Antibody treatments to combat the amyloid peptides leading to Alzheimer's disease have been mostly unsuccessful. But by hiding those antibodies inside nanoparticles based on sugar, researchers have seen success in treating the symptoms in mice.

LED lights may hold the key to better cancer treatment while also easing the side effects of existing drugs, and the scientists behind the discovery believe it's just the tip of the iceberg in how the disease could be tackled in the future.

The FDA has approved a new drug for patients in the early-stages of Alzheimer's disease but growing concerns over its safety and real-world efficacy have led to division amongst researchers, with some suggesting it should not be authorized for wide use.

Data from a Phase 1/2 trial has revealed an experimental immunotherapy led to successful response rates in 73% of patients suffering multiple myeloma, a deadly form of blood cancer. An application to the FDA has been filed to bring the drug to market.

According to modeling from the CDC, a pair of Omicron subvariants (BQ.1 & BQ.1.1) now account for half of all SARS.CoV.2 infections in the US. New research also indicates current monoclonal antibody treatments may be ineffective against BQ variants.

In the first big real-world test for monoclonal antibodies against malaria a new study has reported extraordinarily promising results, with a novel therapy found to be 88.2% effective at preventing infections across a six-month period.

A new study has provided more evidence gut bacteria plays a role in the development of rheumatoid arthritis. The research suggests an abnormal immune response to a common species of gut bacteria could influence the development of the disease.

The first successful results from a trial testing a drug designed to slow symptoms of Alzheimer’s have been revealed, but experts suggest more data is needed to understand exactly how meaningful this treatment will be for patients in the real world.

Positive Phase 3 trial results for a new antibody treatment targeting rheumatoid arthritis have recently been reported. The therapy is hoped to offer a new option to patients struggling with current treatments and should be available within the next year.